Conference Paper

CRYSTAL STRUCTURES OF TELMISARTAN TRIHYDRATE
1
Choriev O.E., 
1
Amanov B.Sh., 
2
Alimnazarov B.X.,
3
Ibragimov A.B., 
4
Ashurov J.M. 
1
Termez branch of Tashkent state technical university, Termez, Uzbekistan.
2
Termez State University, Termez, Uzbekistan 
3
Institute of General and Inorganic chemistry of the Academy of Sciences of the Republic of 
Uzbekistan 
4
Institute of bioorganic chemistry of the Academy of Sciences of the Republic of Uzbekistan.
Telmisartan (2-(4-{[4-methyl-6-(1-methyl-1H-1,3-benzodiazol2-yl)-2propyl-1H-1,3-
benzodiazol-1-yl]methyl}phenyl)benzoic 
acid) 
increases blood potassium levels. Moreover, 
telmisartan has dual mode of action may provide 
protective benefits against the vascular and renal 
damage caused by diabetes and cardiovascular 
disease. This molecule is highly lipophilic (
logP
= 7.2) and has two pKa values, 4.7 
(benzimidazole) and 6.7 (carboxyl) [1, 2]. The 
molecule of telmisartan offers one acidic (H-
bond donor) and two basic (H-bond acceptor) 
functionalities, which represent suitable synthons 
(O–H
⋯
O, O–H
⋯
N, N–H
⋯
O, and N–H
⋯
N) for 
the formation of multicomponent crystals.
We have studied crystallographic characterization of telmisartan trihydrate, with the 
cell parameters:
a=13.0215(12)Å,
b=15.4899(11)Å,
c=16.3873(13)Å,
α=91.410(5)
o
,
β=92.602(6)
o
,
γ=110.127(7)
o
,
V=3097.4(4)Å
3
.
Fig. 1. Part of the crystal structure with hydrogen bonds shown as dashed lines. For clarity, H 
atoms not involved in hydrogen bonding are not shown. 
In the crystal structure, a water molecule is connected to N atom of the first 
benzimidazole ring. The carboxylic group hydrogen atom forms H-bond with the second 
benzimidazole 
ring 
N-atom 
(Fig. 1).
Fig.2. Crystal structures of 
telmisartan trihydrate 
The organic molecules are 
stacked in parallel along the 
c
axis 
with 
a 
distance 
of 
16.3873(13) 
Å. 
Water 
molecules are located in the 
channels formed by telmisartan 
along the 
c
axis (Fig.2.).
 

---

Техник ва технологик фанлар со
ҳ
аларининг инновацион масалалари. ТДТУ ТФ 2020 
207 
References 
1. E. Cagigal, L. Gonza'lez, R. M. Alonso and R. M. Jime'nez, J. Pharm. Biomed. Anal., 2001, 
26, 477–486. 
2. E. C. Demiralay, B. Cubuk, S. A. Ozkan and G. Alsancak, J. Pharm. Biomed. Anal., 2010, 
53, 475–482